Watts Water Technologies (NYSE:WTS) Q4 2025 Earnings call February 12, 2026 09:00 AM ET Speaker9Welcome to Watts Water Technologies, Inc. fourth quarter and full year 2025 earnings call. At the end of the presentation, we will open the line for questions. I will now turn the call over to Diane McClintock, Chief Financial Officer. Please go ahead.Speaker3Thank you, and good morning, everyone. Joining me today is Bob Pagano, President and CEO. Before we begin, I'd like to remind everyone that during this call ...

Financial Data and Key Metrics Changes - Net sales for Q2 2025 were $132.5 million, compared to $130.8 million in Q2 2024, reflecting a slight increase [7] - The company incurred a diluted loss of $1.05 per share, while adjusted diluted earnings per share were $0.41, down from $0.47 per share in the same period last year [7] - For the six months ended June 28, 2025, net sales totaled $268.2 million, with a diluted loss of $0.57 per share, compared to $267.6 million in sales and $0.87 per share in diluted earnings for the same period in 2024 [8] - Cash and short-term investments amounted to $101 million, with a current ratio of 4.0:1 and no debt [8] Business Line Data and Key Metrics Changes - New product sales accounted for $42 million, or 34% of net firearm sales, indicating an increase from Q1 2025 [14] - The company conducted a product rationalization that resulted in a $5.7 million reduction in sales due to SKU reductions, particularly affecting the American Gen one and EC9 pistols [18][19] Market Data and Key Metrics Changes - The firearms industry is experiencing softening demand, with NICS checks falling below pre-2019 levels, impacting manufacturing, distribution, and retail channels [15] - Despite market challenges, the company is reportedly outpacing the market in terms of demand, with a focus on maintaining market share [31] Company Strategy and Development Direction - The company has reorganized its operations to enhance flexibility and accountability, aiming for sustainable growth and resilience in a cyclical market [5] - The acquisition of Anderson Manufacturing for $16 million is expected to expand capacity and product offerings, reinforcing the company's position in the firearms market [12][13] - The company emphasizes innovation and market share gain as key strategies in a down market [31] Management's Comments on Operating Environment and Future Outlook - Management acknowledges macroeconomic pressures such as tariff and interest rate uncertainty, a weakening job market, and inflation affecting consumer spending [15] - The company remains committed to delivering reliable and innovative products while operating with financial discipline and maximizing shareholder value [16] Other Important Information - The company returned $23 million to shareholders through dividends and stock repurchases, maintaining a dividend strategy of approximately 40% of net income [10] - The organizational realignment is not primarily a cost-saving initiative but rather a reallocation of talent to better align with future strategies [27] Q&A Session Summary Question: Impact of product rationalization on sales - The product rationalization primarily affected the American Gen one and EC9 pistols, with a $5.7 million reduction in sales [18][19] Question: Organizational realignment and long-term savings - The organizational realignment is complete, focusing on reallocating talent rather than generating ongoing savings [27][28] Question: Current consumer demand for firearms - The company is outpacing the market in demand, with a focus on producing SKUs that customers want [31]

Financial Data and Key Metrics Changes - The company reported total revenue of $32.9 million for Q1 2025, an 18% increase from $27.9 million in Q1 2024, primarily driven by growth in the biologics product family [5][12] - Adjusted EBITDA for Q1 2025 was $3 million, compared to an adjusted EBITDA loss of $1 million in Q1 2024 [15] - Net income for Q1 2025 was $58,000, or $0.00 per share, compared to a net loss of $4.4 million, or $0.03 per share, in the same period last year [15] Business Line Data and Key Metrics Changes - The biologics product family experienced significant growth, while spinal implant sales declined by 10% or $1.2 million year over year [12] - The company launched two new innovative products, Trivium and FiberX, aimed at rejuvenating its core demineralized bone offerings [8] - The company anticipates mid double-digit revenue growth in its biologics product family for the fiscal year 2025 [10] Market Data and Key Metrics Changes - The company received royalties from licensing its Simply Max Q code to a distributor in the chronic wound care space, which is expected to generate additional income [9] - CMS has extended the local coverage determination for skin substitutes to December 31, 2025, potentially increasing royalty income [9] Company Strategy and Development Direction - The company has achieved full vertical integration of its biologics products, marking a significant strategic milestone [7] - The focus is on self-sustainability, profitability, and cash generation, with a targeted revenue guidance for 2025 in the range of $127 million to $131 million, representing 8% to 11% growth [11] - The company is rationalizing its hardware product lines to optimize cash management [10] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the company's future, emphasizing the importance of being realistic regarding government policy impacts on revenue [22] - The company is focused on maintaining its growth in the biologics sector while managing the transition in its hardware offerings [24] - Management expects steady revenue growth throughout the remainder of the year, with cash flow from operations anticipated to improve in Q4 [27] Other Important Information - The company terminated a restrictive investor rights agreement with OrbiMed, which is seen as a positive development for shareholders [6] - The company has added processing capacity at its Belgrade facility to support growing production needs [9] Q&A Session Summary Question: What are the assumptions for incremental minimum payments and royalties from the Amneal deals? - Management has not included additional minimums under the royalty agreement and assumes full manufacturing under the manufacturing license agreement for the remainder of 2025 [19][20] Question: Can you walk through the different drivers for growth in the biologics business? - Key drivers include growth from Amneal and VBM, with a focus on transitioning customers to new product lines [23][24] Question: How should we think about EBITDA and cash flow through the rest of the year? - Cash flow from operations is expected to be tighter in Q3 but improve in Q4, with steady revenue growth anticipated [27] Question: What is the outlook for sales and marketing expenses? - Sales and marketing expenses are expected to increase in Q2 and beyond, aligning more closely with Q4 of the previous year [32] Question: Will there be margin improvements from in-house production? - Management expects margin improvements from bringing production in-house, particularly for products like Fibrex and Trivium [34][35]